A 5-Year Observational Study of Patients With Treatment-Resistant Depression Treated With Vagus Nerve Stimulation or Treatment as Usual: Comparison of Response, Remission, and Suicidality.

Autor:	Aaronson, Scott T., Sears, Peter, Ruvuna, Francis, Bunker, Mark, Conway, Charles R., Dougherty, Darin D., Reimherr, Frederick W., Schwartz, Thomas L., Zajecka, John M.
Předmět:	NEURAL stimulation PHYSIOLOGICAL effects of antidepressants ANTIDEPRESSANTS MENTAL depression DEPRESSED persons MEDICAL care DIAGNOSIS of mental depression THERAPEUTICS DIAGNOSIS of bipolar disorder BIPOLAR disorder CHRONIC diseases COMPARATIVE studies ELECTROCONVULSIVE therapy LONGITUDINAL method RESEARCH methodology MEDICAL cooperation PSYCHOLOGICAL tests RESEARCH VAGUS nerve EVALUATION research TREATMENT effectiveness SUICIDAL ideation ACQUISITION of data IMPACT of Event Scale PSYCHOLOGY
Zdroj:	American Journal of Psychiatry; Jul2017, Vol. 174 Issue 7, p640-648, 9p
Abstrakt:	Objective: The Treatment-Resistant Depression Registry investigated whether adjunctive vagus nerve stimulation (VNS) with treatment as usual in depression has superior long-term outcomes compared with treatment as usual only.Method: This 5-year, prospective, open-label, nonrandomized, observational registry study was conducted at 61 U.S. sites and included 795 patients who were experiencing a major depressive episode (unipolar or bipolar depression) of at least 2 years' duration or had three or more depressive episodes (including the current episode), and who had failed four or more depression treatments (including ECT). Patients with a history of psychosis or rapid-cycling bipolar disorder were excluded. The primary efficacy measure was response rate, defined as a decrease of ≥50% in baseline Montgomery-Åsberg Depression Rating Scale (MADRS) score at any postbaseline visit during the 5-year study. Secondary efficacy measures included remission.Results: Patients had chronic moderate to severe depression at baseline (the mean MADRS score was 29.3 [SD=6.9] for the treatment-as-usual group and 33.1 [SD=7.0] for the adjunctive VNS group). The registry results indicate that the adjunctive VNS group had better clinical outcomes than the treatment-as-usual group, including a significantly higher 5-year cumulative response rate (67.6% compared with 40.9%) and a significantly higher remission rate (cumulative first-time remitters, 43.3% compared with 25.7%). A subanalysis demonstrated that among patients with a history of response to ECT, those in the adjunctive VNS group had a significantly higher 5-year cumulative response rate than those in the treatment-as-usual group (71.3% compared with 56.9%). A similar significant response differential was observed among ECT nonresponders (59.6% compared with 34.1%).Conclusions: This registry represents the longest and largest naturalistic study of efficacy outcomes in treatment-resistant depression, and it provides additional evidence that adjunctive VNS has enhanced antidepressant effects compared with treatment as usual in this severely ill patient population. [ABSTRACT FROM AUTHOR]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu